Search

Liqin Liu

from Vienna, VA
Age ~61
Get Report
Also known as:
Liqi N Liu, Qin Liu Li, Liu Liqin, Liu Ligin
Phone and address:
1419 Stanbridge Pl, Vienna, VA 22182
(703) 980-4205
Related to:
Li YaoLijun Li, 68Ren LiRebecca Y Liu, 45
Connected to:
Abraham C Liu, 109Adele T Liu, 65Adi P Liu, 35Alan Y Liu, 39Albert Y Liu, 36Alen K Liu, 39Alma R Liu, 73Amanda T Liu, 54Ambrose M Liu, 52An P Liu, 59

Liqin Liu Phones & Addresses

  • 1419 Stanbridge Pl, Vienna, VA 22182 (703) 980-4205
  • Washington, DC
  • 9840 Lakepointe Dr, Burke, VA 22015 (703) 764-0873
  • Springfield, VA

Publications

Us Patents

Optimized Gp41-Binding Molecules And Uses Thereof

View page
US Patent:
20210246194, Aug 12, 2021
Filed:
May 13, 2019
Appl. No.:
17/055805
Inventors:
- Rockville MD, US
- Durham NC, US
Jeffrey Lee Nordstrom - Olney MD, US
Liqin Liu - Woodland Hills CA, US
Leslie S. Johnson - Rockville MD, US
Scott Koenig - Rockville MD, US
Barton F. Haynes - Durham NC, US
Guido Ferrari - Durham NC, US
Assignee:
MacroGenics, Inc. - Rockville MD
Duke University - Durham NC
International Classification:
C07K 16/10
C07K 16/28
A61K 39/42
A61K 45/06
Abstract:
The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART diabodies), BiTEs, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that comprise any of such gp41-Binding Molecules, and to methods involving the use of any of such gp41-Binding Molecules in the treatment of HIV-1 infection.

Bispecific Molecules Comprising An Hiv-1 Envelope Targeting Arm

View page
US Patent:
20200354439, Nov 12, 2020
Filed:
Jun 2, 2020
Appl. No.:
16/890380
Inventors:
- Durham NC, US
- Rockville MD, US
- Chapel Hill NC, US
Leslie S. JOHNSON - Rockville MD, US
Chia-Ying Kao LAM - San Jose CA, US
Julia A. SUNG - Chapel Hill NC, US
David M. MARGOLIS - Chapel Hill NC, US
Liqin LIU - Germantown MD, US
Jeffrey Lee NORDSTROM - Olney MD, US
Assignee:
Duke University - Durham NC
MacroGenics, Inc. - Rockville MD
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C07K 16/10
C07K 16/28
C07K 16/44
A61K 39/395
A61K 39/42
A61K 45/06
C07K 16/46
Abstract:
The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.

Bi-Specific Monovalent Diabodies That Are Capable Of Binding Cd19 And Cd3, And Uses Thereof

View page
US Patent:
20200216537, Jul 9, 2020
Filed:
Mar 3, 2020
Appl. No.:
16/807514
Inventors:
- Rockville MD, US
Ezio Bonvini - Potomac MD, US
Chia-Ying Kao Lam - San Jose CA, US
Paul A. Moore - North Potomac MD, US
Liqin Liu - Germantown MD, US
Scott Koenig - Rockville MD, US
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07K 16/28
C07K 16/46
C07K 16/30
A61K 39/395
Abstract:
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.

Multi-Chain Polypeptide-Containing Tri-Specific Binding Molecules That Specifically Bind To Multiple Cancer Antigens

View page
US Patent:
20200207850, Jul 2, 2020
Filed:
Mar 13, 2020
Appl. No.:
16/818893
Inventors:
- Rockville MD, US
Ling HUANG - Rockville MD, US
Gurunadh Reddy CHICHILI - Rockville MD, US
Kalpana SHAH - Rockville MD, US
Chia-Ying Kao LAM - Rockville MD, US
Stephen James BURKE - Rockville MD, US
Liqin LIU - Rockville MD, US
Paul A. MOORE - Rockville MD, US
Ezio BONVINI - Rockville MD, US
Bhaswati BARAT - Rockville MD, US
International Classification:
C07K 16/28
C07K 16/30
Abstract:
The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

Bispecific Molecules Comprising An Hiv-1 Envelope Targeting Arm

View page
US Patent:
20180148497, May 31, 2018
Filed:
Sep 29, 2015
Appl. No.:
15/514420
Inventors:
- Durham NC, US
- Rockville MD, US
- Chapel Hill NC, US
Leslie S. JOHNSON - Rockville MD, US
Chia-Ying Kao LAM - San Jose CA, US
Julia A. SUNG - Chapel Hill NC, US
David M. MARGOLIS - Chapel Hill NC, US
Liqin LIU - Germantown MD, US
Jeffrey Lee NORDSTROM - Olney MD, US
Assignee:
Duke University - Durham NC
MacroGenics, Inc. - Rockville MD
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C07K 16/10
C07K 16/28
A61K 39/42
A61K 45/06
A61K 39/395
C07K 16/46
A61K 39/00
Abstract:
The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.

Bi-Specific Monovalent Diabodies That Are Capable Of Binding Cd19 And Cd3, And Uses Thereof

View page
US Patent:
20170247452, Aug 31, 2017
Filed:
Sep 22, 2015
Appl. No.:
15/514334
Inventors:
- Rockville MD, US
Ezio Bonvini - Potomac MD, US
Chia-Ying Kao Lam - San Jose CA, US
Paul A. Moore - North Potomac MD, US
Liqin Liu - Germantown MD, US
Scott Koenig - Rockville MD, US
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07K 16/28
Abstract:
CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.

Tri-Specific Binding Molecules And Methods Of Use Thereof

View page
US Patent:
20170198045, Jul 13, 2017
Filed:
May 29, 2015
Appl. No.:
15/313741
Inventors:
- Rockville MD, US
Ling Huang - Bethesda MD, US
Gurunadh Reddy Chichili - Germantown MD, US
Kalpana Shah - Boyds MD, US
Chia-Ying Kao Lam - Foster City CA, US
Stephen James Burke - Mount Airy MD, US
Liqin Liu - Germantown MD, US
Paul A. Moore - North Potomac MD, US
Ezio Bonvini - Potomac MD, US
Bhaswati Barat - Derwood MD, US
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
C07K 16/28
C07K 16/30
Abstract:
The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

Bi-Specific Monovalent Diabodies That Are Capable Of Binding Cd19 And Cd3, And Uses Thereof

View page
US Patent:
20170157251, Jun 8, 2017
Filed:
Dec 5, 2016
Appl. No.:
15/369360
Inventors:
- Rockville MD, US
Leslie S. Johnson - Darnestown MD, US
Scott Koenig - Rockville MD, US
Chia-Ying Kao Lam - Foster City CA, US
Liqin Liu - Germantown MD, US
Paul A. Moore - North Potomac MD, US
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
A61K 39/395
A61K 31/519
C07K 16/30
C07K 16/28
Abstract:
The present invention is directed to a combination therapy involving the administration of: (1) a bi-specific molecule capable of specifically binding to CD19 and to CD3 (i.e., a CD19×CD3 bi-specific molecule), and (2) a Bruton's Tyrosine Kinase (BTK) inhibitor for the treatment of disease, in particular treatment of a disease associated with or characterized by the expression of CD19. Preferably, such a CD19×CD3 bi-specific molecules are bi-specific monovalent diabodies. The invention is directed to pharmaceutical compositions that contain such a CD19×CD3 bi-specific molecule, a BTK inhibitor, or a combination of such agents. The invention is additionally directed to methods for the use of such pharmaceutical compositions in the treatment of disease, in particular, treatment of a cancer associated with or characterized by the expression of CD19.

Isbn (Books And Publications)

Jun Shi Ke Xue Wen Xian Xin Xi Jian Suo Jiao Cheng

View page
Author

Liqin Liu

ISBN #

7801372557

Control profile
Liqin Liu from Vienna, VA, age ~61 Get Report